Adriatic
Argentina
Asia-Pacific
Australia and New Zealand
Bangladesh
Belgique (Belgium)
België (Belgium)
Brasil (Brazil)
Bulgaria
Canada
Canada
Česká republika (Czech Republic)
Chile
中国 (China)
Colombia
Costa Rica
Србија (Serbia)
Danmark (Denmark)
Deutschland (Germany)
Ecuador
España (Spain)
Europe
France
Ελλάδα (Greece)
香港特区 (Hong Kong SAR)
Indian Subcontinent
Ireland
Israel ישראל
Italia (Italy)
日本 (Japan)
Latinoamérica
Magyarország (Hungary)
México (Mexico)
Middle East and North Africa
Nederland (Netherlands)
Norge (Norway)
Österreich (Austria)
Panama
Portugal
Paraguay
Perú (Peru)
Polska (Poland)
Российская Федерация (Russia)
Puerto Rico
Romania
Schweiz (Switzerland)
Slovenská republika (Slovak Republic)
Southeast Asia
South Africa and Sub-Sahara
대한민국 (South Korea)
Suisse (Switzerland)
Suomi (Finland)
Sverige (Sweden)
台湾地区 (Taiwan)
Türkiye (Turkey)
United Kingdom
United States
Uruguay
Україна (Ukraine)
Press releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 22, 2022- New InterStim X™ system provides 10 to 15 years of battery life without the need to recharge
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation...
-
Jan 24, 2022Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration approval of its Intellis™ rechargeable neurostimulator and...
Jan 14, 2022DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators DUBLIN, Jan. 14, 2022 /PRNewswire/ -- Medtronic plc...
-
Jan 12, 2022
Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain DUBLIN, Jan. 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
-
Dec 13, 2021Study shows 57.1% of patients discontinued or reduced oral opioid prescription refills post-procedure and exhibited a decrease in payer costs¹
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the results of a study published in Osteoporosis International that demonstrate a decrease, and in some cases...